Safe Haven Investment Portfolio Stocks: Pitney Bowes (NYSE:PBI), Lamb Weston Holdings (NYSE:LW)

Pitney Bowes Inc. (NYSE:PBI) runs in leading trade, it are easing down -0.45% to traded at $15.63. PBI attains analyst recommendation of 1.70 on scale of 1-5 with week’s performance of 0%.

To find out the technical position of PBI, it holds price to book ratio of 22.43 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. It has forward price to earnings ratio of 8.53, and price to earnings ratio calculated as 11.61. The price to earnings growth ration calculated as 2.90. PBI is presenting price to cash flow of 2.86 and free cash flow concluded as 35.74.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 36.20%, and looking further price to next year’s EPS is 6.36%. While take a short look on price to sales ratio, that was 0.84 and price to earning ration of 11.61 attracting passive investors.

Shares of Lamb Weston Holdings, Inc. (NYSE:LW) [Trend Analysis] runs in leading trade, it moving up 1.58% to traded at $37.36. The firm has price volatility of 2.37% for a week and 2.81% for a month. Narrow down four to firm performance, its weekly performance was 0.17% and monthly performance was -0.58%. The stock price of LW is moving up from its 20 days moving average with 1.60% and isolated positively from 50 days moving average with 5.86%. In addition, the firm has price to earnings ratio of 16.96, which is authentic method to judge but not universal for all situation.

Fundament/ News Factor in Focus

Taking look on ratio analysis, LW has forward price to earnings ratio of 16.26, compare to its price to earnings ratio of 16.96. Adding one more ration to find detail valuation of security, price to earnings growth ration that stands at 4.78. The co is presenting price to cash flow as 77.41, the low single digit may indicate stock is undervalued and vice versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower.

The firm has price volatility of 2.49% for a week and 2.80% for a month. Narrow down four to firm performance, its weekly performance was 0.54% and monthly performance was -0.70%.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *